-
1Electronic Resource
مصطلحات الفهرس: high risk patient, hospital admission, hospitalization, human, intestine surgery, major clinical study, male, outcome assessment, pediatric hospital, priority journal, retrospective study, adalimumab/dt [Drug Therapy], adalimumab/pe [Pharmacoeconomics], adalimumab/pv [Special Situation for Pharmacovigilance], azathioprine/dt [Drug Therapy], azathioprine/pd [Pharmacology], azathioprine/pv [Special Situation for Pharmacovigilance], C reactive protein/ec [Endogenous Compound], infliximab/dt [Drug Therapy], infliximab/pe [Pharmacoeconomics], infliximab/pv [Special Situation for Pharmacovigilance], infliximab/tm [Unexpected Outcome of Drug Treatment], methotrexate/dt [Drug Therapy], methotrexate/pd [Pharmacology], methotrexate/pv [Special Situation for Pharmacovigilance], steroid/pd [Pharmacology], steroid/pv [Special Situation for Pharmacovigilance], ustekinumab/dt [Drug Therapy], ustekinumab/pe [Pharmacoeconomics], ustekinumab/pv [Special Situation for Pharmacovigilance], vedolizumab/dt [Drug Therapy], vedolizumab/pe [Pharmacoeconomics], vedolizumab/pv [Special Situation for Pharmacovigilance], disease association, article, child, clinical assessment, clinical outcome, cohort analysis, colon resection, comparative study, controlled study, Crohn disease/di [Diagnosis], Crohn disease/dt [Drug Therapy], Crohn disease/su [Surgery], disease activity, drug dose escalation, female, health care cost, hemicolectomy, Article
URL:
https://repository.monashhealth.org/monashhealthjspui/handle/1/26841
Scandinavian Journal of Gastroenterology
LibKey Link -
2Electronic Resource
المؤلفون: Subramaniam K., Svenningsen L., Baekdal M., Kammerlander H., Walsh A., Boysen T., Bampton P., Radford-Smith G., Kjeldsen J., Andrews J.M., Vestergaard T., Moore G.T., Jensen N.M., Connor S.J., Wildt S., Wilson B., Ellard K., Christensen L.A., Bell S.J., Julsgaard M., Hvas C.L., Gearry R.B., Gibson P.R., Fallingborg J., Sparrow M.P., Bibby B.M., Connell W.R., Brown S.J., Kamm M.A., Lawrance I.C.
مصطلحات الفهرس: budesonide/pv [Special Situation for Pharmacovigilance], infliximab/cb [Drug Combination], infliximab/cm [Drug Comparison], infliximab/dt [Drug Therapy], infliximab/pv [Special Situation for Pharmacovigilance], mercaptopurine/cb [Drug Combination], mercaptopurine/dt [Drug Therapy], mercaptopurine/pv [Special Situation for Pharmacovigilance], mesalazine/pv [Special Situation for Pharmacovigilance], prednisolone/dt [Drug Therapy], prednisolone/pv [Special Situation for Pharmacovigilance], tumor necrosis factor antibody/cb [Drug Combination], tumor necrosis factor antibody/dt [Drug Therapy], tumor necrosis factor antibody/to [Drug Toxicity], tumor necrosis factor antibody/pv [Special Situation for Pharmacovigilance], mesalazine/dt [Drug Therapy], adult, adverse outcome, article, attitude to illness, Australia, cohort analysis, controlled study, Crohn disease/dt [Drug Therapy], Denmark, disease activity, female, fetus, gestational age, human, inflammatory bowel disease/dt [Drug Therapy], low birth weight, major clinical study, male, medical information, New Zealand, newborn, patient counseling, patient satisfaction, prediction, pregnancy outcome, pregnant woman, priority journal, prospective study, questionnaire, recurrence risk, risk assessment, third trimester pregnancy, treatment response, ulcerative colitis/dt [Drug Therapy], adalimumab/cb [Drug Combination], adalimumab/cm [Drug Comparison], adalimumab/dt [Drug Therapy], adalimumab/pv [Special Situation for Pharmacovigilance], allopurinol/cb [Drug Combination], allopurinol/dt [Drug Therapy], allopurinol/pv [Special Situation for Pharmacovigilance], budesonide/dt [Drug Therapy], Article
URL:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29311
Inflammatory Bowel Diseases
Click here for full text options
LibKey Link -
3Electronic Resource
المؤلفون: Subramaniam K., Svenningsen L., Baekdal M., Kammerlander H., Walsh A., Boysen T., Bampton P., Radford-Smith G., Kjeldsen J., Andrews J.M., Vestergaard T., Moore G.T., Jensen N.M., Connor S.J., Wildt S., Wilson B., Ellard K., Christensen L.A., Bell S.J., Julsgaard M., Hvas C.L., Gearry R.B., Gibson P.R., Fallingborg J., Sparrow M.P., Bibby B.M., Connell W.R., Brown S.J., Kamm M.A., Lawrance I.C.
مصطلحات الفهرس: budesonide/pv [Special Situation for Pharmacovigilance], infliximab/cb [Drug Combination], infliximab/cm [Drug Comparison], infliximab/dt [Drug Therapy], infliximab/pv [Special Situation for Pharmacovigilance], mercaptopurine/cb [Drug Combination], mercaptopurine/dt [Drug Therapy], mercaptopurine/pv [Special Situation for Pharmacovigilance], mesalazine/pv [Special Situation for Pharmacovigilance], prednisolone/dt [Drug Therapy], prednisolone/pv [Special Situation for Pharmacovigilance], tumor necrosis factor antibody/cb [Drug Combination], tumor necrosis factor antibody/dt [Drug Therapy], tumor necrosis factor antibody/to [Drug Toxicity], tumor necrosis factor antibody/pv [Special Situation for Pharmacovigilance], mesalazine/dt [Drug Therapy], adult, adverse outcome, article, attitude to illness, Australia, cohort analysis, controlled study, Crohn disease/dt [Drug Therapy], Denmark, disease activity, female, fetus, gestational age, human, inflammatory bowel disease/dt [Drug Therapy], low birth weight, major clinical study, male, medical information, New Zealand, newborn, patient counseling, patient satisfaction, prediction, pregnancy outcome, pregnant woman, priority journal, prospective study, questionnaire, recurrence risk, risk assessment, third trimester pregnancy, treatment response, ulcerative colitis/dt [Drug Therapy], adalimumab/cb [Drug Combination], adalimumab/cm [Drug Comparison], adalimumab/dt [Drug Therapy], adalimumab/pv [Special Situation for Pharmacovigilance], allopurinol/cb [Drug Combination], allopurinol/dt [Drug Therapy], allopurinol/pv [Special Situation for Pharmacovigilance], budesonide/dt [Drug Therapy], Article
URL:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29311
Inflammatory Bowel Diseases
LibKey Link